Kang Enbei, which has been suspended for one month, today announced a major asset restructuring plan. It plans to acquire 42.3 million shares of Zhejiang Zhencheng Pharmaceutical for 233 million yuan. After the completion of the acquisition, it will hold Zhencheng Medicine, which was purchased from Kang Enbei in December last year. After the equity of % Zhencheng Pharmaceutical, it was less than half a year after the acquisition, and the holding of Zhencheng Medicine means that Kang Enbei has entered the pharmaceutical e-commerce. At the same time, Kang Enbei also said that it will increase its capital by 30 million yuan to participate in the 20% stake in Jiaxing Yikang, thus trying to enter the field of in vitro diagnostics and smart wear. Conba will continue to suspend trading.
Restructuring Holdings Zhencheng Medicine
The Kang Enbei restructuring plan shows that the company intends to acquire a total of 42.3 million shares of Zhencheng Pharmaceutical held by 15 counterparties in the form of cash, including Ruirui Holdings, Tonglian Ventures, Shanghai Sinopharm and Wei Jian, accounting for the total share capital of Zhencheng Pharmaceutical. The proportion is 26.44%, and the share price of this part is 233 million yuan. Upon completion of the transaction, the company will hold a total of 57.25% of Zhencheng Pharmaceutical as its largest shareholder.
The total equity value of Zhencheng Pharmaceutical's shareholders is 880 million yuan, and the assessed value added is 465 million yuan, with a value-added rate of 112.18%. Zhencheng Pharmaceutical has a medical B2B e-commerce platform independently developed and operated, “Pharmaceutical Onlineâ€. Huatai Securities has issued a report saying that Kang Enbei will use the Internet virtual integration model such as “Zhencheng Network†and “Pharmaceutical Union 50,000†and “Yunlian Qianshang†to gain more channels and logistics distribution capabilities to achieve online and offline The integration and mutual promotion of channel business is conducive to enhancing the breadth and depth of product marketing. Some OTC varieties are expected to be quickly boosted by online.
It is worth mentioning that Zhencheng Medicine has twice smashed the GEM. In 2010 and 2012, the company submitted the application for listing on the GEM twice, but for the first time, due to the small scale of operations, the application materials were withdrawn, and the second time was due to the “Chromium Excess Capsule†industry event and The customer bill dispute was withdrawn and declared. At the same time, the company also submitted a listing application to the New Third Board in September 2014, but withdrawal of the application materials due to the transfer of shares of the company in December last year.
At the same time, Kang Enbei also transferred 18.75% equity of Zhenming Mingye and 7,084,500 shares of Tianshikang for 54.375 million yuan and 42.648 million yuan respectively. After the transaction is completed, it will wholly-owned and cherish the pharmaceutical industry, and hold the day. Shikang 57.96% equity.
Invest in smart wear and in vitro diagnostics
Kang Enbei also announced the announcement of foreign investment, and plans to invest 30 million yuan to acquire 20% equity of Jiaxing Yikang by means of capital increase and shareholding. The capital contribution was completed in two phases. In the first phase, the company invested 20 million yuan to obtain 15% equity of Jiaxing Yikang. After the first phase of the company's capital contribution, Jiaxing Yikang invested 8 million yuan to acquire 100% equity of Nanjing Jingkang and Hangzhou Jingyihao held by Li Zhihua and its related parties. . The company will invest 10 million yuan in the three months after March 31, 2016 to obtain the right to choose the 5% equity of the target company.
According to the data, Jiaxing Yikang focuses on bedside monitoring and wearable medical fields, and has a Nanhu District-level technology research and development center and a colloidal gold detection technology center. Nanjing Jingkang is a high-tech bio-diagnostic reagent, which specializes in the production of high-tech detection products such as enzyme-linked immunoassay, chemiluminescence diagnostic reagents and intelligent medical instruments. The main products of Hangzhou Yiyihao are medical and household intelligent medical testing instruments and biological diagnostic reagent products. The hospitals, medical institutions, medical examination centers, and household products are selected as the target markets. The three companies have 6 technology production platforms (Zhenkang Bio is the platform for R&D and production of enzyme-linked immunoassay and chemiluminescence technology; Yikang Bio is the research and development platform for colloidal gold rapid diagnosis technology and intelligent portable instruments; Chemical technology research and development production platform), both independent product systems and synergy.
However, Jiaxing Yikang is still in a state of loss. According to financial data, in 2014, Jiaxing Yikang achieved operating income of 40,200 yuan and net profit of -1,184,900 yuan. From January to March 2015, it realized operating income of 140,000 yuan. The profit is -24.94 million yuan.
Kang Enbei mentioned that the investment of Jiaxing Yikang tried to enter the field of in vitro diagnostic reagents and smart wearable devices. Diagnostic reagents are a tentative action for the company to break through the pharmaceutical industry. The field of smart wearable devices is the company's perfect Internet pharmaceutical industry chain. An important part.
Kang Enbei has suspended trading since April 28, and the company's share price has been strong daily before the suspension.
Jiangsu Asbao Medical Technology Co., Ltd. , https://www.iigloves.com